Living with Fatty Liver Disease

Chapter 1: What Is Fatty Liver Disease (and Why the Name Just Changed)

You got a diagnosis, and it probably came with a name you'd never heard before, or worse, a name that changed since the last time your doctor mentioned it. That alone can feel disorienting. Here's what's actually going on inside your liver, and then the naming mess, because the words matter less than what they describe.

The 5 Percent Line

Your liver is supposed to have some fat in it. A small amount is normal tissue chemistry, nothing to worry about. The problem starts when fat builds up past roughly 5 percent of the liver's total weight. Cross that line and you have what doctors call hepatic steatosis: fatty liver, in plain terms.

Picture the liver as a busy sorting facility that processes everything you eat and drink, breaking down nutrients, filtering toxins, making proteins your blood needs. When more fat arrives than the facility can process and ship out, it starts piling up in storage. That pile is the steatosis your scan or biopsy is describing.

For most people, that's where it stays: fat sitting quietly in liver cells, causing no damage on its own. For some, the excess fat eventually triggers inflammation, and that's a different, more serious situation. We'll get into what separates those two paths in the next few chapters. Right now, the important thing to understand is that a fatty liver diagnosis is not a verdict. It's a description of what a scan or blood test found on one particular day.

Why the Name Changed in 2023

If you've done any research already, you may have run into three different acronyms for what looks like the same thing: NAFLD, MASLD, and now MASH instead of NASH. Here's what happened and why.

For decades, this condition was called NAFLD, non-alcoholic fatty liver disease. In 2023, a large international group of liver specialists, working through the American Association for the Study of Liver Diseases and partner organizations in Europe, formally retired that name. Two problems drove the change.

First, "non-alcoholic" defines the disease by what it isn't, and it told you nothing about what was actually causing the fat buildup. Second, patients and clinicians both raised concerns that the word "fatty" in a diagnosis, delivered without context, felt stigmatizing, as if the condition were simply a matter of willpower rather than biology.

The replacement name, MASLD, stands for Metabolic Dysfunction-Associated Steatotic Liver Disease. It puts the actual driver, metabolic dysfunction, right in the name. Metabolic dysfunction covers things like insulin resistance, elevated blood sugar, high triglycerides, and abdominal weight gain. These are measurable, treatable biological processes, not character flaws.

The same overhaul renamed NASH (non-alcoholic steatohepatitis) to MASH (Metabolic dysfunction-Associated Steatohepatitis). MASH describes the more advanced stage, where fat has triggered inflammation and active liver cell injury.

A third term came out of this same relabeling: MetALD. This one covers people who meet the criteria for MASLD but also drink alcohol above a certain amount, roughly more than 140 grams a week for women or 210 grams a week for men, according to the guidance that introduced the term. MetALD acknowledges that metabolic factors and alcohol can both be acting on the liver at the same time, rather than forcing every case into an either-or box. If your chart uses this term, it means your care team sees both factors as relevant to your case, not that alcohol is the sole cause.

If your paperwork still says NAFLD or NASH, don't read anything into it. Plenty of clinics, lab systems, and insurance forms are still catching up to the 2023 change. The underlying biology is the same disease either way.

One Condition, Several Stops Along the Way

MASLD, MASH, and MetALD aren't three separate diseases. They're points on a single continuum, and understanding that continuum is probably the single most useful thing you can take from this chapter.

At one end sits a healthy liver with minimal fat. Moving along the spectrum, you reach simple steatosis, fat buildup without significant inflammation, which is where most people who get this diagnosis actually land. Continue further and some people progress to MASH, where inflammation has entered the picture. From there, sustained inflammation can produce fibrosis, scar tissue that gradually replaces healthy liver tissue. At the far end is cirrhosis, where scarring has become extensive enough to impair how the liver functions.

Movement along this spectrum is not automatic, and it's not one-directional either. Simple steatosis often stays simple steatosis for years, or improves substantially with changes in weight, blood sugar control, and activity level. Chapter 3 walks through the fibrosis stages in detail, including what separates mild from severe and why your specific stage, more than the diagnosis label itself, is what actually shapes your treatment plan.

The Numbers Behind Your Diagnosis

If part of what you're feeling right now is isolation, the statistics argue against that reaction. An estimated 37.5 percent of people worldwide have some form of steatotic liver disease, and about 33.6 percent have MASLD specifically. In the United States, MASLD affects roughly one in four adults, an estimated 80 to 100 million people. That makes it the most common chronic liver condition in the country, ahead of hepatitis and alcohol-related liver disease combined.

The connection to broader metabolic health explains why the numbers run so high. Up to 75 percent of people with obesity have MASLD, a figure that climbs to about 90 percent among people with severe obesity. More than half of people with type 2 diabetes have it too. These aren't coincidental overlaps. Insulin resistance, the biological state underlying type 2 diabetes, directly increases how much fat the liver stores and produces, which is exactly why the 2023 renaming shifted the focus to metabolic dysfunction in the first place.

A diagnosis still takes some adjusting to. But the biology here traces to insulin signaling, fat metabolism, and genetics: mechanisms your body runs largely outside of conscious control. About one in five people with MASLD go on to develop MASH, meaning the majority, four in five, do not. Where your particular case falls on that spectrum is a question for the tests covered in Chapter 6.

What This Chapter Covered

A fatty liver diagnosis means liver fat has climbed above roughly 5 percent of the organ's weight. In 2023, the medical field renamed NAFLD to MASLD and NASH to MASH, and added a third category, MetALD, for cases where alcohol use and metabolic factors overlap. All three sit on one spectrum running from steatosis through MASH to fibrosis and cirrhosis, and most people diagnosed today are caught at the earliest, most modifiable point on that spectrum. Worldwide, more than a third of adults have some form of this condition, and in the United States it affects roughly 1 in 4, making your diagnosis one of the most common findings in modern medicine.

End of free sample. The full book picks up right where this leaves off.